Diadexus (DDXS) Stock Price, News & Analysis

Company Overview

Diadexus, Inc. is a life sciences company specializing in the development, manufacturing and commercialization of in vitro diagnostic tests and instruments for cardiovascular, inflammatory and other chronic diseases. Leveraging proprietary immunoassay and enzyme assay platforms, the company offers a portfolio of products designed to aid physicians in assessing patient risk and monitoring disease progression through minimally invasive blood testing. Its core business is built upon diagnostic kits, reagents and supporting instrumentation that deliver quantitative biomarker measurements in clinical and research laboratory settings.

The company’s flagship assays focus on lipoprotein-associated phospholipase A₂ (Lp-PLA₂), an enzyme linked to vascular inflammation and cardiovascular risk. Diadexus markets both automated and manual enzyme-linked immunosorbent assays (ELISAs) under the PLAC test brand, which have received regulatory clearances for cardiovascular risk stratification. In addition to Lp-PLA₂ testing, the firm’s pipeline includes novel immunoassays targeting markers of neurodegenerative disorders and other inflammatory conditions, positioning it to expand into related diagnostic markets.

Headquartered in South San Francisco, California, Diadexus operates a centralized testing laboratory and research facility that supports both domestic and international distribution. Through partnerships with clinical laboratories, distributors and strategic collaborators, its products reach healthcare providers and research institutions across North America, Europe and select markets in Asia. The company’s quality systems comply with international regulatory standards, including ISO 13485 and relevant U.S. Food and Drug Administration guidelines.

Founded in 1988, Diadexus has evolved from an early-stage diagnostics startup into a publicly traded company on the OTC Markets. Under the leadership of Chief Executive Officer Robert Dumas and a management team with deep experience in in vitro diagnostics, the company continues to invest in assay development, manufacturing scale-up and market expansion. Diadexus remains committed to advancing precision medicine by delivering reliable biomarker information to support patient care and clinical research.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 30 shs
• Average Volume: 15,481 shs
• Market Capitalization: $53 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DDXS Stock Analysis - Frequently Asked Questions

How were Diadexus' earnings last quarter?

Diadexus, Inc. (OTCMKTS:DDXS) released its quarterly earnings results on Monday, October, 26th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.35.

How do I buy shares of Diadexus?

Shares of DDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Diadexus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diadexus investors own include GoPro (GPRO), GE Aerospace (GE), Ambarella (AMBA) and Alliqua Biomedical (ALQA).

Company Calendar

• Last Earnings: 10/26/2015
• Today: 7/14/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:DDXS
• CIK: 1036968
• Web: www.diadexus.com
• Phone: (650) 246-6400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,100,000
• Free Float: N/A
• Market Cap: $53 thousand
• Optionable: Not Optionable
• Beta: N/A